Skip to main content
Equibles
ARAY logo

ARAY · Accuray Inc · Metrics

Track ARAY — free

Use ARAY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARAY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.30 +0.02 (+6.69%)
Rebalance outlook locked
Customer concentration — top customer 17% of revenue

One customer — 17% of revenue (the three months ended March 31, 2026)

“The JV represented approximately 17% and 21% of our total net revenue during the three months ended March 31, 2026 and 2025 respectively, and represented approximately 16% and 27% of our total net revenue during the nine months ended March 31, 2026 and 2025 respectively.”

One customer — 16% of revenue (the nine months ended March 31, 2026)

“The JV represented approximately 17% and 21% of our total net revenue during the three months ended March 31, 2026 and 2025 respectively, and represented approximately 16% and 27% of our total net revenue during the nine months ended March 31, 2026 and 2025 respectively.”

One customer — 13% of receivables (As of March 31, 2026)

“As of March 31, 2026, and June 30, 2025, the JV represented approximately 13% and 33%, respectively, of our total accounts receivable balance.”
View the 10-Q filed May 6, 2026
Market Cap
$33.56M
Shares
119.44M
Volume · Oct 5 2.16M Avg daily vol (3M) 7.14M

ARAY metrics

77 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.28
Market cap
$33.56M

Price action

20 metrics
Price change (1W)
+27.7%
Price change (30D)
+4.1%
Price change (3M)
+12.4%
Price change (6M)
-33.1%
Price change (YTD)
-65.7%
Price change (1Y)
-83.0%
Trailing year
Price change (5Y)
-93.1%
52-week high
$1.85
52-week low
$0.22
Change from 52-week high
-84.8%
Change from 52-week low
+27.7%
Annualized volatility
112.4%
Annualized volatility (3M)
120.5%
Beta
2.5
RSI (14D)
56.7
Price vs SMA 50
+6.3%
Price vs SMA 200
-35.9%
Avg volume (3M)
7.14M
Relative volume
0.7
Average dollar volume
$2.11M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
119.44M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 1,197.6%
P / book
0.8
reciprocal yield 124.2%
FCF yield
-38.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-146.6%

Historical valuation

8 metrics
P / E historical average (3Y)
58.0×
reciprocal yield 1.7%
P / E historical average (5Y)
58.0×
reciprocal yield 1.7%
EV / revenue historical average (3Y)
0.6×
reciprocal yield 165.4%
EV / revenue historical average (5Y)
0.7×
reciprocal yield 138.5%
EV / EBIT historical average (3Y)
446.5×
reciprocal yield 0.2%
EV / EBIT historical average (5Y)
259.7×
reciprocal yield 0.4%
EV / EBITDA historical average (3Y)
54.2×
reciprocal yield 1.8%
EV / EBITDA historical average (5Y)
40.1×
reciprocal yield 2.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-19

Profitability

9 metrics
Gross margin
27.7%
Operating margin
-6.6%
Trailing 12 months
Net margin
-12.2%
Gross profit (TTM)
$111.45M
Operating profit (TTM)
−$26.44M
Net income (TTM)
−$49.19M
Trailing 12 months
Diluted EPS (TTM)
$-0.29
FCF margin
-3.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.35

Growth

11 metrics
Revenue growth YoY
-20.9%
Year over year
Net income growth YoY
-272.8%
Revenue (TTM)
$401.95M
Trailing 12 months
EPS growth YoY
-650.0%
Shares change YoY
+16.6%
Year over year · more shares
Revenue CAGR (3Y)
-3.5%
Revenue CAGR (5Y)
+0.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-118.0%
Return on assets
-11.1%
Debt / equity
3.5
Current ratio
1.5
EBITDA (TTM)
−$18.50M
Free cash flow (TTM)
−$12.84M
Quick ratio
0.7
Interest coverage
-0.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$40.62M
Total assets
$443.68M
Total debt
$147.87M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.98M
Capital expenditures (TTM)
$5.86M
R&D (TTM)
$37.75M
SG&A (TTM)
—
Stock compensation (TTM)
$6.46M
R&D / revenue
9.4%
Stock compensation / revenue
1.6%

Ownership (13F)

3 metrics
13F filers
112
13F filer change QoQ
-14
Institutional ownership
59.8%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 11.6 days to cover
Days to cover
11.6d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1138723 CUSIP 004397105 13F (30d) 3 filings 3 filers Visit website Investor relations